Widespread use of electronic health records, medication administration records, and pharmacy claims data has allowed health services researchers, pharmacoepidemiologists, and other outcomes researchers to perform rapid analyses that can be used for clinical decision support, policy development, formulary management, and pharmacovigilance. However, missing data in pharmacy claims and other electronic records are common problems with important potential consequences. 1, 2 For example, in the QRISK study, where three-fourths of patients had missing data, there was no association between cholesterol and cardiovascular events based on multiple imputation. However, a complete-case analysis of the same data set yielded a significant association. 3 Researchers who perform statistical inference with missing data risk reporting conclusions that may be invalid. [4] [5] [6] [7] [8] [9] Reliance on methods such as complete-case analysis, where the missing data are ignored and observations are dropped from analysis, may be appropriate if the missing data mechanism is missing completely at random (MCAR). 6, [10] [11] [12] An example of MCAR would be the absence of a laboratory value because a test tube randomly fell out of a rack while being transported. In this situation, there is no causal link between the absence of the data and the actual laboratory value. However, in situations where missing data cannot be confirmed to be MCAR, the absent data is deemed missing at random (MAR). In MAR, researchers should consider whether more sophisticated methods are needed to estimate the missing data. 6, 10, 11 According to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), proper reporting of missing data should include an explanation of methods used to handle missing data. 13 In practice, however, missing data are commonly unreported in observational research. 14, 15 A review of a subset of randomized trials between July and December 2001 published in the British Medical Journal, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine reported that 89% of the 71 studies reviewed had partial or missing data. 15 The authors concluded that 92% of studies unjustifiably used completecase analysis to handle missing data.
Multiple imputation is one form of missing data analysis appropriate to a missing data mechanism that is MAR. 6, 12, [16] [17] [18] [19] [20] The multiple imputation method inputs plausible values for missing data based on the observed values. Multiple imputation is a process of imputation that creates multiple data sets using regression methods and data simulations. 6, 16, 19 Each simulated data set is analyzed using standard methods (e.g., logistic regression), which are then combined to produce outcomes estimates and confidence intervals (CIs).
This article provides health services researchers, pharmacoepidemiologists, outcomes researchers, and decision makers with a demonstration of multiple imputation to support the published results of an observational study that relied on complete-case analysis. 21 After a brief description of the original study, we compare multiple imputation and complete-case analysis results. We conclude with a discussion of our research implications in the context of pharmacy research. Appendix 1 provides details of the multiple imputation method.
Objective
A previous study evaluated the association between medication adherence levels and improvements in lipid profile. 21 That analysis used a complete-case analysis that removed subjects who did not have a complete list of values for all variables in the multiple regression model. We sought to investigate whether multiple imputation would yield different conclusions from the complete-case analysis.
Methods

Case Study
We used data from a previous publication 21 as a case study to compare findings of a completecase analysis with the findings of an analysis that applied multiple imputation for missing data. The retrospective cohort study evaluated the association between adherence to statin medication for dyslipidemia and a 25% or greater change in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TGs). Further details of the observational study are described elsewhere. 21 
Study Population
The study population 21 was drawn from the Veterans Integrated Systems Network 22 (Desert Pacific Healthcare Network) that includes VA facilities in the Southern California (Los Angeles, Long Beach, Loma Linda, and San Diego) and Nevada (Las Vegas) regions that servicẽ 1.4 million veterans. 22 Patients were included if they were a new statin user between the periods of November 30, 2006 , and December 2, 2007, with a diagnosis of dyslipidemia (or related disorders) based on the International Classification of Disease, Ninth Revision (Appendix 1), older than 18 years, and had been continuously enrolled in the VA health plan for at least 2 years. 21 Patients were considered new statin users as defined by a 6-month washout period before filling their first statin prescription. Patients were followed for a 1-year observation period after the index date on LDL-C, non-HDL-C, and TGs. Subjects were required to be eligible for VA medical and pharmacy services 6 months prior to the index date and throughout the study period. Patients were excluded if they switched statins during the 12-month follow-up period or had an admission for more than 30 consecutive days. The Veterans Affairs San Diego Healthcare System and University of California, San Diego, institutional review board granted exemption status for the study protocol. 21 
Summary Measure
Adherence was the main exposure variable of interest and categorized into adherent or nonadherent based on a medication possession ratio (MPR) threshold level of 0.80. Patients who were at or above the threshold were considered adherent; patients who were below the threshold were considered nonadherent. 21 MPR was calculated as the days supplied of prescription medication divided by the number of days the subject was designated to be on therapy during the study period. 23, 24 The dependent variable was reduction in lipid panel levels for LDL-C, non-HDL-C, and TGs at 12 months. In terms of study end points, subjects were dichotomized into those that achieved a 25% or greater reduction from baseline or those that had less than a 25% reduction from baseline for each lipid type. 21 A 25% reduction in atherogenic lipids was described in prior studies as a clinically significant improvement. 25, 26 Multiple Imputation Analysis Using the data from the study, 21 we applied multiple imputation to address the missing data. This framework requires several data assumptions. First, the pattern of missing values is considered missing at random. 6, 19, 27, 28 Second, the variables in the multivariate model should have a normal distribution. 6 Finally, all subjects must have some observed values for imputation to proceed. 7 To address sampling variability, five data sets were created using multiple imputation, and the effect estimates were averaged. 6 Appendix 1 provides further details about multiple imputation.
Data Analysis
In this case study, 21 a variable was created for all subjects that indicated whether each individual had missing data or otherwise. Balance of demographic characteristics for patients with and without missing data was then evaluated to confirm assumptions of MAR data.
A logistic regression model was used to evaluation the association between adherence and lipid reduction. OR estimates and CIs from the regression models using multiple imputation were compared with complete-case analysis and crude estimates. Crude estimates were included to reflect the unadjusted model. Statistical significance was defined as p<0.05. Data analysis was performed using SAS v.9.3 (Cary, NC). Details about the logistic regression model are provided in Appendix 1.
Results
A total of 7739 patients were identified based on the inclusion and exclusion criteria. Overall, 78% of the patients (6074) had complete values and were included in the complete-case analysis. For the complete-case analysis, 2827 (47%) of the subjects were adherent (MPR of 0.80 or higher) and 3247 (53%) were nonadherent 
Comparison of Subjects with Missing and Complete Data
Similar gender proportions were observed for groups with missing data for baseline values for LDL-C, HDL-C, and TGs compared with groups with complete data (95.67%, 95.65%, and 95.88% vs 95.85%, 95.32%, and 95.28%, respectively). A higher proportion of patients with complete data were categorized as adherent compared with those with missing data for baseline LDL-C, HDL-C, and TGs (38.70%, 38.96%, and 39.14% vs 46.26%, 46.26%, and 46.17%, respectively) ( Table 2) .
Regression Findings
The logistic regression model for the multivariate analysis controlled for age, BMI, gender, baseline lipid values, comorbid conditions (diabetes, hypertension, congestive heart failure, history of myocardial infarction, angina, and vascular disease), statin use, ethnicity, and starting medication count. The regression results for the crude, complete-case analysis, and multiple imputation method were similar with CI overlap for all lipid panel end points ( Table 3 ). The ORs (95% CIs) in achieving a 25% or greater reduction in LDL-C for crude, complete-case, and multiple imputation analyses were 3.5 (95% CI 3.1-3.9), 4.3 (95% CI 3.8-4.9), and 4.1 (95% CI 3.7-4.6), respectively.
The crude ORs (95% CIs) in achieving a 25% or greater reduction in non-HDL-C for crude, complete-case, and multiple imputation analyses were 3.5 (95% CI 3.1-3.9), 4.5 (95% CI 4.0-5.2), and 4.4 (95% CI 3.9-4.9), respectively. The ORs (95% CIs) in achieving a 25% or greater reduction in TGs for crude, compete-case, and multiple imputation analyses were 3.1 (95% CI 2.8-3.6), 4.0 (95% CI 3.5-4.6), and 4.1 (95% CI 3.6-4.6), respectively. 
Discussion
In this case study, the use of multiple imputation did not alter the conclusions of the complete-case and crude analyses. It functions as a supporting sensitivity analysis that the completecase conclusions were appropriate despite the absence of data for 22% of patients. We cannot conclude necessarily that multiple imputation has eliminated missing data bias because this would require having the missing data to determine. It does serve as a robust data-driven approach to reduce uncertainty in estimates by using all available data for estimation rather than discarding observations because of absent values.
Researchers with an interest in using large databases should consider performing missing data analysis to confirm the results of completecase analysis. Ideally, this would be performed in conjunction with the primary complete-case analysis in accord with the STROBE recommendations. 9 If there is suspicion that missing data could influence results, systematic examination of the possible effects should be conducted. Given the growing importance of research based on electronic medical records and its application in clinical care, mitigating the risk of spurious conclusions due to missing data demands greater attention. Multiple imputation applications are now included in commonly used statistical software packages including those available at no charge. Hence production of robust results is accessible to researchers in virtually any setting. ProporƟon of missing data Figure 1 . Proportion of missing data for several variables in the observational study. The proportions of missing data for the other baseline parameters were 0%. BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TGs = triglycerides. Inclusion of multiple imputation results can serve to strengthen the veracity of the conclusions. Most statistical software (e.g., SAS, SPSS, and STATA) utilizes complete-case analysis for multiple regression models by default. Researchers unaware of this default setting may find a reduction in their study sample size and altered CIs when performing analyses. This article serves to illuminate the common and routinely ignored phenomenon of missing data. We accomplished this by examining a real-world data set to quantify the amount of missing data and attempted to address it.
A study limitation is the possibility of having a missing data pattern where the absence of data is reflective of the outcome. This scenario is termed not missing at random (NMAR). An example of NMAR data would be a survey conducted to determine the relationship between worker satisfaction and the number of hours worked per week in which information was missing for all employees working overtime who were too busy to respond to the survey. No statistical method is currently available to determine if the missing data pattern was either MAR or NMAR. Application of multiple imputation with NMAR data may amplify bias rather than eliminate bias. 29 To ensure that NMAR was not a sizable risk, we compared several baseline characteristics (age, gender, and adherence status) between the patient sample with missing data and the patient sample with complete data.
The importance of using electronic medical records and pharmacy claims data for assessing outcomes, performance measurement, and health care forecasting has grown exponentially as the analysis of large data sets has become easier for researchers. 30 Clinical decision making and health care policy rely increasingly on statistical analyses of medication records and pharmacy-derived claims. However, the absence of complete data is common in electronic medical records and pharmacy claims data that are designed for clinical management, not necessarily investigational studies. Prior research found that missing data can influence the results and conclusions generated from studies based on pharmacy claims records. 1 Few studies appropriately address missing data or describe the methods applied to contend with the absence of study information. 15 The convenience of assuming data is MCAR is offset by the knowledge that missing data bias may potentially reverse the study findings.
In this report, we describe a method to account systematically for missing data to validate findings of a complete-case analysis that measured the association between adherence and atherogenic lipid reduction in statin users. This was motivated by the potential loss of large portions of study data when complete-case analysis is performed for pharmacy investigations. Health services researchers, pharmacoepidemiologists, and other outcomes researchers using electronic medical records could benefit from additional analyses that account for the missing data to bolster the robustness of study findings.
Conclusions
The use of multiple imputation for addressing missing data did not alter conclusions that relied on a complete-case analysis, despite missing data for 22% of study subjects. Application of missing data methods served as statistical support that findings from the complete-case analysis were robust. Multiple imputation represents a valid and accessible means of accounting for missing data. also grateful for additional validation provided by Josephine N. Tran. We appreciate the helpful comments from the reviewers that strengthened this manuscript.
